This study focused on 21 advanced-stage HER2-mutated NSCLC patients who received first-line treatment with a pyrotinib-based regimen from a cohort of 144 HER2-mutated NSCLC patients at Jiangsu Province People’s Hospital. Here, ERBB2 is linked to non-small cell lung carcinoma.